AU2005226927B2 - Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423) - Google Patents

Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423) Download PDF

Info

Publication number
AU2005226927B2
AU2005226927B2 AU2005226927A AU2005226927A AU2005226927B2 AU 2005226927 B2 AU2005226927 B2 AU 2005226927B2 AU 2005226927 A AU2005226927 A AU 2005226927A AU 2005226927 A AU2005226927 A AU 2005226927A AU 2005226927 B2 AU2005226927 B2 AU 2005226927B2
Authority
AU
Australia
Prior art keywords
dosage form
pharmaceutical dosage
form according
coated
coat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005226927A
Other languages
English (en)
Other versions
AU2005226927A1 (en
Inventor
Marija Bogataj
Manica Cerne
Greta Cof
Rok Dreu
Janez Kerk
Anton Lavric
Tatjana Mateovic
Ales Mrhar
Shizuko Muraoka
Anton Stalc
Doris Tibaut
Uros Urleb
Fumio Yoneda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of AU2005226927A1 publication Critical patent/AU2005226927A1/en
Application granted granted Critical
Publication of AU2005226927B2 publication Critical patent/AU2005226927B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005226927A 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423) Ceased AU2005226927B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SIP200400094 2004-03-26
SI200400094 2004-03-26
PCT/EP2005/003175 WO2005092295A1 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Publications (2)

Publication Number Publication Date
AU2005226927A1 AU2005226927A1 (en) 2005-10-06
AU2005226927B2 true AU2005226927B2 (en) 2010-09-23

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005226927A Ceased AU2005226927B2 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)

Country Status (15)

Country Link
US (1) US20100183714A1 (https=)
EP (1) EP1734933B1 (https=)
JP (1) JP2007530492A (https=)
CN (1) CN1956707B (https=)
AR (1) AR048342A1 (https=)
AT (1) ATE468846T1 (https=)
AU (1) AU2005226927B2 (https=)
BR (1) BRPI0509271A (https=)
CA (1) CA2559685A1 (https=)
DE (1) DE602005021475D1 (https=)
MY (1) MY145329A (https=)
PE (1) PE20051163A1 (https=)
RU (1) RU2375047C2 (https=)
TW (1) TW200600121A (https=)
WO (1) WO2005092295A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
ES2627745T3 (es) * 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
EP3915552A1 (en) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
BR112018077032A2 (pt) * 2016-06-23 2019-04-02 Nutrivert Llc método para aprimorar o crescimento ou a conversão alimentar em um animal, uso de pgn, mdp ou um análogo de mdp na preparação de um medicamento e pgn, mdp ou um análogo de mdp
WO2018085935A1 (en) * 2016-11-09 2018-05-17 Engene, Inc. Intestinal expression of programmed death ligand 1
BR112019012071A2 (pt) * 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
EP3554485B9 (en) * 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
EP3554342B1 (en) * 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
ES3014076T3 (en) 2020-03-26 2025-04-16 Nutrivert Inc Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477912B1 (en) * 1990-09-27 2001-08-29 Univerza V Ljubljani, Fakulteta Za Farmacijo Novel N-acyldipeptides, and pharmaceutical compositions containing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2113221C1 (ru) * 1990-05-04 1998-06-20 Ииссум Рисерч Дивелопмент Компани оф дзе Хебрю Юниверсити оф Иеруcалим Фармацевтическая форма для введения лекарственного средства в ободочную кишку, способ введения лекарственного препарата и способ получения матриц для такой формы
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477912B1 (en) * 1990-09-27 2001-08-29 Univerza V Ljubljani, Fakulteta Za Farmacijo Novel N-acyldipeptides, and pharmaceutical compositions containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Moriguchi et al (1999) Arzneim-Forsch./Drug Research, 49(1):184-192 *
Ochi et al (1999) Arzneim-Forsch./Drug Research, 49(1):72-79 *

Also Published As

Publication number Publication date
ATE468846T1 (de) 2010-06-15
PE20051163A1 (es) 2006-02-21
EP1734933A1 (en) 2006-12-27
US20100183714A1 (en) 2010-07-22
RU2006137660A (ru) 2008-05-10
CA2559685A1 (en) 2005-10-06
EP1734933B1 (en) 2010-05-26
AU2005226927A1 (en) 2005-10-06
CN1956707A (zh) 2007-05-02
JP2007530492A (ja) 2007-11-01
BRPI0509271A (pt) 2007-09-04
AR048342A1 (es) 2006-04-19
MY145329A (en) 2012-01-31
RU2375047C2 (ru) 2009-12-10
DE602005021475D1 (de) 2010-07-08
CN1956707B (zh) 2010-12-29
WO2005092295A1 (en) 2005-10-06
TW200600121A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
ES2568746T3 (es) Sistemas de liberación pulsátil controlada
AU2003246792B2 (en) Oral suspension of active principle microcapsules
EP1123087B1 (en) Oral pulsed dose drug delivery system
JP4436475B2 (ja) 固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末
JP2653996B2 (ja) 徐放性薬剤
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
JP2007532689A (ja) 医薬有効成分の遅延性かつ調節性放出のための微粒子経口ガレヌス製剤
JPH02289512A (ja) 徐放性医薬製剤
KR20080059409A (ko) 즉시방출형 및/또는 조절방출형 특성을 가진 약제학적 제형
AU2005226927B2 (en) Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)
JP5778184B2 (ja) 上皮増殖因子の経口投与可能薬学的ペレット
JP2004505034A (ja) 制御された放出のシグモイドパターンを示すエレトリプタンの粒状組成物
WO2004024128A2 (en) Modified release ketoprofen dosage form
JP2005075826A (ja) 多孔質シリカ担体を含有する徐放性製剤
AU2005261958A1 (en) Granules for controlled release of Tamsulosin
WO2009065130A2 (en) Modified release formulations of diltiazem
JP4723243B2 (ja) ペリンドプリルの遅延及び制御放出のためのマイクロカプセル
EP0956006A1 (en) Colonic delivery of weak acid drugs
JP2646851B2 (ja) 胃内滞留製剤
WO2010036975A2 (en) Dipyridamole and acetylsalicylic acid formulations and process for preparing same
KR100858631B1 (ko) 인다파미드가 함유된 서방형 펠렛
WO2007138557A2 (en) Controlled-release multiple unit pharmaceutical compositions
MXPA99003093A (en) Colonic delivery of weak acid drugs
MXPA03007749A (es) Granulos de liberacion controlada que comprenden un nucleo de silice porosa.
BR122013000700B1 (pt) "suspension microcapsules in a net stage aquasa"

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired